fibrinopeptide-a has been researched along with Venous-Thrombosis* in 2 studies
1 review(s) available for fibrinopeptide-a and Venous-Thrombosis
| Article | Year |
|---|---|
[Fibrinopeptide A (FPA), fibrinopeptide B (FPB) and fibrinopeptide Bbeta(15-42) (FPBbeta15-42)].
Topics: Biomarkers; Blood Coagulation Tests; Cerebral Infarction; Disseminated Intravascular Coagulation; Fibrin Fibrinogen Degradation Products; Fibrinopeptide A; Fibrinopeptide B; Humans; Immunoenzyme Techniques; Myocardial Infarction; Peptide Fragments; Pulmonary Embolism; Radioimmunoassay; Thrombophilia; Venous Thrombosis | 2004 |
1 other study(ies) available for fibrinopeptide-a and Venous-Thrombosis
| Article | Year |
|---|---|
[The clotting tests and molecular markers in evaluating of coagulation alterations against the background of anti-thrombotic prevention by Dabigatran after large orthopedic operations].
The large orthopedic operations are associated with high risk of development of thrombosis of deep veins of lower extremities. Nowadays, new oral anticoagulants are widely applied for anti-thrombotic prevention. The coagulation alterations against the background of effect of Dabigatran, a direct inhibitor of thrombin were examined in 30 patients underwent endoprosthesis replacement of knee joint. The routine clotting indices, fibrinopeptid A, soluble fibrin-monomeric complexes, D-dimer. The samples of blood were selected before operation, after 30 minutes, and at 1st, 3d, 7th and 14th day after endoprosthesis replacement of knee joint. It is demonstrated that routine clotting tests and also detection of D-dimer and soluble fibrin-monomeric complexes provide no adequate evaluation of coagulation activity in patients underwent large orthopedic operation. The concentration of specific marker of fibrin formation of fibrinopeptid A continues to be increased no less than two weeks after endoprosthesis replacement of knee joint that testifies keeping hyper-coagulation and risk of thrombosis. The intake of Dabigatran etexilate in fixed dosage does not exclude development of thrombosis of deep veins of lower extremities that substantiates point of view concerning usefulness of individualization of anti-thrombotic prevention in case of application of new oral anti-coagulants. Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Female; Fibrin; Fibrin Fibrinogen Degradation Products; Fibrinopeptide A; Humans; Knee Joint; Male; Middle Aged; Postoperative Complications; Thrombin; Venous Thrombosis | 2017 |